Given the crosstalk of pathways triggered between different nuclear receptors, it may be possible that in the near future, breast cancer therapeutic decisions may require consideration of the expression of all four major steroid hormone receptors in breast cancer— ER, PR, AR and GR. This evidence concerns the gene NR3C1 and breast cancer.